Bioavailability Enhancement

:: Overview :: Poorly Soluble Drugs :: Poorly Permeable Drugs


Enhancing bioavailability has become a vital need within the pharmaceutical and biopharmaceutical industries. This need is growing as rational drug design and high throughput screening generate thousands of new chemical entities (NCEs) for disease targets. These NCEs are usually hydrophobic in nature, with increased receptor binding affinities. Due to these and other properties, more than 60% of new drug actives currently under development are insufficiently soluble/permeable to allow for acceptable oral dosage formulations.

In order to help overcome such challenges, Pharmaterials has developed its IntraSOLV® and MacroSOLV® formulation technologies to facilitate the development of poorly soluble and poorly absorbed drugs. For more information about these technologies, please view the rest of this section.